$1.52
2.01% today
Nasdaq, Sep 19, 10:00 pm CET
ISIN
US67577R1023
Symbol
IRD

Ocuphire Pharma Inc Stock price

$1.52
+0.41 36.94% 1M
+0.37 32.17% 6M
+0.33 27.73% YTD
+0.07 4.47% 1Y
-0.60 28.30% 3Y
-6.92 81.99% 5Y
-291.28 99.48% 10Y
-5.68 78.89% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
+0.03 2.01%
ISIN
US67577R1023
Symbol
IRD
Industry

Key metrics

Basic
Market capitalization
$89.3m
Enterprise Value
$57.8m
Net debt
positive
Cash
$32.4m
Shares outstanding
59.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.8 | 6.0
EV/Sales
3.8 | 3.9
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
69.4%
Return on Equity
-225.0%
ROCE
-186.5%
ROIC
490.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$15.4m | $14.8m
EBITDA
$-34.4m | $8.8m
EBIT
$-34.5m | $-36.5m
Net Income
$-58.3m | $-39.5m
Free Cash Flow
$-31.8m
Growth (TTM | estimate)
Revenue
-6.3% | 34.7%
EBITDA
-151.9% | 128.0%
EBIT
-152.1% | -16.5%
Net Income
-313.0% | 31.3%
Free Cash Flow
-177.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-223.3% | 59.4%
EBIT
-223.6%
Net
-377.9% | -267.1%
Free Cash Flow
-206.4%
More
EPS
$-0.9
FCF per Share
$-0.5
Short interest
0.1%
Employees
-
Rev per Employee
-
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ocuphire Pharma Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
88%
Hold
13%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
66% 66%
129%
- Research and Development Expense 30 30
65% 65%
194%
-34 -34
152% 152%
-223%
- Depreciation and Amortization 0.04 0.04
300% 300%
0%
EBIT (Operating Income) EBIT -34 -34
152% 152%
-224%
Net Profit -58 -58
313% 313%
-378%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
7 days ago
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards...
Neutral
GlobeNewsWire
15 days ago
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced that the first patient has been dosed in LYNX-3, the Company's pivotal Phase 3 clinical trial evaluating Phentola...
Neutral
GlobeNewsWire
16 days ago
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jay...
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today